Difference between revisions of "Part:BBa K3733007"
Yuanhui Sun (Talk | contribs) |
|||
| Line 5: | Line 5: | ||
LTA is a novel antimicrobial peptide (AMP), whose design was based on combing the active centers of a ride range of AMPs, including LL-37, YW12D, innate defense regulator 1, and cathelicidin 2 with thymopentin or the active center of thymosin alpha 1 (Tα1). It could neutralize Lipopolysaccharides (LPS), thus effectively blocking the downstream inflammation pathway. | LTA is a novel antimicrobial peptide (AMP), whose design was based on combing the active centers of a ride range of AMPs, including LL-37, YW12D, innate defense regulator 1, and cathelicidin 2 with thymopentin or the active center of thymosin alpha 1 (Tα1). It could neutralize Lipopolysaccharides (LPS), thus effectively blocking the downstream inflammation pathway. | ||
| − | + | ||
===Usage and Biology=== | ===Usage and Biology=== | ||
Revision as of 13:43, 20 October 2021
LTA: A novel antimicrobial peptide
LTA is a novel antimicrobial peptide (AMP), whose design was based on combing the active centers of a ride range of AMPs, including LL-37, YW12D, innate defense regulator 1, and cathelicidin 2 with thymopentin or the active center of thymosin alpha 1 (Tα1). It could neutralize Lipopolysaccharides (LPS), thus effectively blocking the downstream inflammation pathway.
Usage and Biology
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]